Sign In
Buy ISEE
$39.95
+0 (+0%)
At Close: Oct 09, 2023
Jazz (JAZZ) Enrols First Patient in Essential Tremor Study
03:26pm, Thursday, 16'th Dec 2021 Zacks Investment Research
Jazz Pharmaceuticals (JAZZ) enrolls the first patient in a phase IIb study to evaluate JZP385 for essential tremor.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
11:20am, Wednesday, 15'th Dec 2021 Zacks Investment Research
Sector ETF report for PTH
Bellus (BLU) Stock Surges on Data From Chronic Cough Study
10:19pm, Tuesday, 14'th Dec 2021 Zacks Investment Research
Bellus Health (BLU) achieves the primary endpoint in a phase IIb study evaluating BLU-5937 for the treatment of refractory chronic cough.
Intellia (NTLA) Begins Dosing in Hereditary Angioedema Study
10:17pm, Tuesday, 14'th Dec 2021 Zacks Investment Research
Intellia (NTLA) doses the first patient in a phase I/II study to evaluate NTLA-2002 as a single-dose therapy for preventing attacks in patients having hereditary angioedema.
Iveric Bio Appoints Tony Gibney as Executive Vice President and Chief Business and Strategy Officer
10:08pm, Monday, 13'th Dec 2021 Kwhen Finance
Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021
04:48pm, Monday, 13'th Dec 2021 Zacks Investment Research
Angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fails to achieve the primary endpoint.
Heron's (HRTX) Zynrelef Gets FDA Nod for Label Expansion
12:22pm, Friday, 10'th Dec 2021 Zacks Investment Research
The FDA grants label expansion to Heron???s (HRTX) Zynrelef for pain relief after small to medium abdominal surgeries, lower extremity total joint replacements, and foot and ankle surgeries in adults.
Reata (RETA) Falls on Negative Advisory Committee Outcome
04:18pm, Thursday, 09'th Dec 2021 Zacks Investment Research
An FDA advisory committee believes Reata's (RETA) bardoxolone study data does not support the effectiveness of the candidate in slowing the progression of CKD in patients with Alport syndrome.
Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq
03:38pm, Thursday, 09'th Dec 2021 Zacks Investment Research
Affimed (AFMD) starts recruiting patients in a phase I/IIa study to evaluate the combination of AFM24 and Roche's atezolizumab in solid tumors.
Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug
03:26pm, Tuesday, 07'th Dec 2021 Zacks Investment Research
The FDA raises concerns related to data in Reata's (RETA) NDA seeking approval for bardoxolone for treating Alport syndrome. An advisory committee meeting is scheduled tomorrow.
7 A-Rated Biotechs to Buy for the Long Run
11:58am, Friday, 03'rd Dec 2021
The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.
Vertex (VRTX) Up on Kidney Disease Drug's Success in Phase II
03:13pm, Thursday, 02'nd Dec 2021 Zacks Investment Research
Vertex's (VRTX) APOL1 inhibitor, VX-147, led to a significant reduction in protein in urine in a phase II study in APOL1-mediated FSGS, a severe kidney disorder.
AbbVie (ABBV) Files for Skyrizi to Treat Crohn's Disease in EU
06:52pm, Wednesday, 01'st Dec 2021 Zacks Investment Research
AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn's disease.
Jazz (JAZZ) Begins Zepzelca Combo Study for First-Line SCLC
06:38pm, Wednesday, 01'st Dec 2021 Zacks Investment Research
Jazz Pharmaceuticals (JAZZ) and partner Roche enrol the first patient in the phase III study to investigate the novel combination of Zepzelca and Tecentriq for small cell lung cancer.
Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study
09:01pm, Tuesday, 30'th Nov 2021 Zacks Investment Research
The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.
